

**Sydney 15 December 2005:** Ventracor Limited (ASX: VCR) moved a step closer to completing enrolment in its CE Mark Trial announcing the successful implant of its left ventricular assist device (LVAD), the VentrAssist, at Norway's Rikshospitalet University Hospital.

Ventracor Limited Chief Executive Officer Colin Sutton PhD said: "Clinical knowledge and experience in surgical procedures and patient management is growing rapidly.

"Recent implants in Norway, Perth, Sydney, Auckland and Brisbane bring enrolments in the CE Mark Trial closer to completion.

"We expect there will be additional implants in the coming weeks and are on track to complete recruitment in the CE Mark Trial before the end of the first quarter 2006."

Dr Sutton added Ventracor had developed training programs and added field support which would allow the company to carefully expand the number of European hospitals implanting the VentrAssist LVAD.

Ventracor's CE Mark Trial is aimed at obtaining approval to sell the VentrAssist™ in the major market of Europe.

Dr Sutton added Ventracor continued to focus on achieving key milestones.

#### **About Ventracor**

Ventracor is a global medical device company that has developed a blood pump, the VentrAssist™ left ventricular assist system (LVAS) for patients in cardiac failure. The company hopes to bring the VentrAssist™ to the global market in record time, and expects to obtain a significant share of the huge potential market.

*For further information, please contact:*

*Andrew Geddes  
Manager, Investor Relations  
Ventracor Limited  
+ 61 2 9406 3086*